The biotech industry has made a splash in 2017, outperforming practically all the broad markets. With this incredible display, it's no wonder that investor interest in this particular industry has grown, and…
Many on Wall Street feel that some of the more speculative institutional tech money may be rotating into the biotechs, and with good reason.
The June 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
The top analyst upgrades, downgrades and other research calls from Friday include AK Steel, Altice USA, Biogen, Caterpillar, Gilead Sciences and Oracle.
The May 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
The May 15 short interest data have been compared with the previous report, and moves in the selected biotech stocks were mixed.
With prescription drug spending breaking new records almost every year now, people like to blame Big Pharma and use it as the industry punching bag.
The April 28 short interest data have been compared with the previous report, and moves in the selected biotech stocks were mixed.
Many value investors have flocked to Gilead Sciences as the world's top biotech stock now that it is valued at a lower multiple than Big Pharma rivals.
Jon C. Ogg As of the start of May of 2017, just 21 members of the S&P 500 Index were valued at less than 10 times expected earnings per share.
The April 13 short interest data have been compared with the previous report, and moves in the selected biotech stocks were mixed.
With earnings starting to really snowball next week, and a market that seems to be teetering somewhat due to high valuations and some messy geopolitical issues, it makes sense for investors to…
The March 31 short interest data have been compared with the previous report, and short interest decreased in most of the selected biotech stocks.
A massive new Jefferies research report reminds investors that as a rule the first quarter is traditionally slower for biotechnology stocks.
The health care sector in general has rallied since Trump took over the presidency, but now that his repeal of the ACA fell through, the health care rally is called into question.
